Indication
Treatment of adult patients with unresectable or metastatic well-differentiated extra-pancreatic (epNETs) and pancreatic (pNETs) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues (SSAs).
Medicine details
- Medicine name:
- cabozantinib (Cabozantinib Ipsen)
- SMC ID:
- SMC2967
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Publication due date:
- 10 August 2026
- SMC meeting date:
- 07 July 2026